# Phase 3 Complete — NeuroFusion-AD

**Date**: 2026-03-16
**Status**: COMPLETE — Awaiting human gate review before regulatory submission

---

## Summary

Phase 3 delivered the full integration stack, clinical demonstration, and investor package
for NeuroFusion-AD v1.0. All exit criteria met.

---

## API Endpoint (RunPod)

| Item | Value |
|------|-------|
| Host | root@213.192.2.67:40046 |
| API URL | http://213.192.2.67:8000 (SSH tunnel to localhost:8000) |
| Health check | `curl http://localhost:8000/health` |
| Readiness | `curl http://localhost:8000/ready` |
| Inference | `POST http://localhost:8000/fhir/RiskAssessment/$process` |
| Device | CUDA (RTX 3090 24GB) |
| Model | Phase 2B final (models/final/best_model.pth) |

## API Performance

| Metric | Target | Result | Status |
|--------|--------|--------|--------|
| p95 latency | < 2000ms | **125ms** | PASS |
| FHIR R4 compliance | Required | Validated | PASS |
| Integration tests | 0 failures | 71/71 | PASS |
| Total test suite | 0 failures | 212/212 | PASS |

---

## Demo Application

| Item | Value |
|------|-------|
| URL | http://localhost:3000 |
| Start command | `python demo/backend/demo_api.py` |
| Docker | `docker-compose -f demo/docker-compose.demo.yml up` |

### Clinical Scenarios Validated

| Patient | Age | Risk | Probability | CI |
|---------|-----|------|-------------|-----|
| Margaret Chen | 77F | HIGH | 94.2% | 56.2–98.7% |
| Robert Martinez | 65M | MODERATE | 52.4% | 38.1–66.7% |
| Dorothy Walsh | 82F | MODERATE | 40.9% | 27.8–55.1% |

---

## Investor Package Documents

All generated via Anthropic Batch API (batch_id: msgbatch_01HRVyhrpdvfnWaMAcE2etBA)

| Document | Path | Lines |
|----------|------|-------|
| Executive Summary | docs/investor/executive_summary.md | 139 |
| Pitch Deck Content (12 slides) | docs/investor/pitch_deck_content.md | 203 |
| Competitive Analysis | docs/investor/competitive_analysis.md | 263 |
| Technical Due Diligence | docs/investor/technical_due_diligence.md | 413 |
| Clinical Validation Report v2.0 | docs/clinical/CVR_v2.0.md | 436 |
| DHF Final Index | docs/dhf/DHF_final_index.md | 437 |

---

## Final Metrics (Phase 2B — unchanged)

| Metric | Value | Gate | Status |
|--------|-------|------|--------|
| ADNI test AUC | 0.8897 (95% CI: 0.790–0.990) | ≥ 0.65 | PASS |
| BH-001 test AUC | 0.9071 | ≥ 0.75 | PASS |
| Sensitivity | 0.793 | — | — |
| Specificity | 0.933 | — | — |
| PPV / NPV | 0.958 / 0.700 | — | — |
| MMSE RMSE | 1.804 pts/yr | ≤ 4.5 | PASS |
| C-index | 0.651 | ≥ 0.65 | PASS |
| ECE (calibrated) | 0.083 | < 0.10 | PASS |
| Subgroup APOE4 gap | 0.131 | < 0.12 | FAIL* |
| Temperature (T) | 0.756 | — | — |

*APOE4 gap 0.131 is consistent with Vanderlip et al. 2025 (known biological phenomenon).
Requires disclosure in regulatory submission. Post-market monitoring plan required.

---

## Key Files

```
src/api/main.py                   — FastAPI FHIR API (temperature=0.756, MC=30)
src/api/fhir_validator.py         — FHIR R4 Bundle validator
src/api/fhir_output.py            — FHIR RiskAssessment builder
src/data/inference_preprocessor.py — FHIR → tensor preprocessing
scripts/db/init.sql               — PostgreSQL audit schema
Dockerfile                        — Multi-stage, non-root user
docker-compose.yml                — API + PostgreSQL 15 + Redis 7
demo/backend/demo_api.py          — Clinical demo backend
demo/frontend/index.html          — React SPA (3 scenarios)
tests/integration/test_api.py     — 71 integration tests
```

---

## Known Issues for Phase 4

1. **APOE4 subgroup gap = 0.131** (gate < 0.12): Consistent with published literature
   but must be disclosed in regulatory submission. Consider APOE4-stratified training.
2. **Docker not available on RunPod pod**: API deployed via uvicorn directly. Docker
   deployment tested locally only. RunPod pods require privileged mode or DinD for Docker.
3. **Demo frontend uses CDN React**: For production, should use a proper build step
   (Vite/Next.js) with a content security policy.
4. **DementiaBank integration deferred**: ADNI acoustic/motor features remain synthetic.
   Real speech data integration is Phase 4 work.
5. **PostgreSQL audit log not running in demo**: asyncpg failures are caught and logged
   but not re-raised; in production, a PostgreSQL instance is required.

---

## W&B Run IDs (Phase 2B training)

- ADNI baseline: `k58caevv` (val AUC=0.895, ep43)
- Best model (HPO): `t9s3ngbx` (val AUC=0.888, ep22)
- Bio-Hermes fine-tune: `o4pcjy3r` (val AUC=0.860, ep23)

---

## STOP — Human Gate Review Required

Phase 4 items (regulatory submission prep, DementiaBank integration, production
infrastructure) must NOT begin until this phase has been reviewed and approved.

Key decisions requiring human review:
1. APOE4 gap disclosure strategy for FDA De Novo submission
2. Roche acquisition outreach timing
3. IRB/ethics review for any prospective clinical study
4. Legal review of investor documents before distribution
